FDA cites blood cancer risk linked to TNF blockers in young patients

04/14/2011 | Reuters

The FDA cautioned that a drug class called tumor necrosis factor inhibitors has been associated with hepatosplenic T-cell lymphoma, particularly among teens and young adults. A majority of the cases involved patients treated for ulcerative colitis or Crohn's disease. Labels have been updated for Johnson & Johnson's Remicade and Abbott Laboratories' Humira, the FDA said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL